Karen Pinilla Alba, MD, discusses the safety findings stages 1 and 2 of the phase II/III PARTNER trial in triple negative and/or germline BRCA-mutated breast cancer.
Karen Pinilla Alba, MD, medical oncologist and clinical research fellow at University of Cambridge, discusses the safety findings stages 1 and 2 of the phase II/III PARTNER trial in triple negative and/or germline BRCA-mutated breast cancer.
The PARTNER trial examined the data collected from patients in the first 2 phases of the trial who received olaparib (Lynparza). The results showed that although adverse events were common, the majority of them were grade 1 or 2 and 5% were grade ≥3, explains Pinilla.
The safety data presented at the 2019 San Antonio Breast Cancer Symposium does not provide a comparison with a control arm, but Pinilla believes the number of grade ≥3 adverse events reported did not exceed expectations according to previous clinical trials that assess platinum-based chemotherapy in the neoadjuvant setting.